RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares. RBC Capital Lifts CRISPR Therapeutics (CRSP) Target to $50, Keeps Sector Perform The analysts noted that CASGEVY, CRISPR's leading product, missed its sales expectations in Q3 2025 – revenue from the product was $17 million, compared to a consensus estimate of $41 million. Also, the number of CASGEVY infusions fell from 16 in Q2 to 10 in Q3.? But despite this underperformance, RBC Capital noted that Vertex Pharmaceuticals (CRISPR's partner) projects over $100 million in total CASGEVY revenue for 2025. The analysts see this as an indication of more than $39 million in expected Q4 sales. Separately, on the same day, Citizens affirmed its Market Outperform and an $86 price target on CRISPR stock, citing promising Phase 1 data for its CTX310 treatment. This treatment targets and destroys blood fats, specifically ANGPTL3, which contrib
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]Seeking Alpha
- CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]Seeking Alpha
- What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- CRSP's page on the SEC website